Current approaches, challenges and future directions for monitoring treatment response in prostate cancer

Journal of Cancer

Volumn 5, Issue 1, 2014, Pages 3-24

  Wallace, T J ^a,b   Torre, T ^a,b   Grob, M ^c   Yu, J ^c   Avital, I ^a   Brucher B L D M ^a,d   Stojadinovic, A ^a,d   Man, Y G ^a,e  

^a Bon Secours Health System   (United States)

^b Virginia Urology   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Theodor Billroth Adademy ^*  (Germany)

^e Hospital of Nanjing   (China)

Author keywords

Monitoring treatment response; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; APC PROTEIN; BIOLOGICAL MARKER; BONE SPECIFIC ALKALINE PHOSPHATASE; GLUTATHIONE TRANSFERASE P1; MICRORNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SARCOSINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; CRYOTHERAPY; DIGITAL RECTAL EXAMINATION; FOCAL THERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MDA CRITERIA; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCIST CRITERIA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; REVIEW; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; TREATMENT RESPONSE MONITORING; TUMOR BIOPSY; TUMOR CLASSIFICATION;

EID: 84893637357     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7709     Document Type: Review

References (157)

1. [Internet] Howladder N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feur EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. http://cancer.gov/csr/1975_2010/
2. [Internet] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. http://www.nccn.org.
3. Alberta Provincial Genitourinary Tumour Team. Prostate cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care. 2011. (Clinical practice guideline; no. GU-004).
4. [Internet] http://www.nice.org.uk/CG058
5. Thompson I et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106-2131.
6. Heidenreich A et al. Guidelines on Prostate Cancer. Eur Urol. 2008;53(1):68-80.
7. Wilt TJ, MacDonald R, Rutks I et al. Systematic Review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-448.
8. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103-106.
9. Hanks GE, Pajak TF, Porter I, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2002;21:3972-3978.
10. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516-2527.
11. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904-1911.
12. Dearnaley DP, Mason MD, Parmar MK, et al. Adjuvant therapy with sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009; 10:872-876.
13. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Canc Inst. 2002;94:1458-1468.
14. Smith MR, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S45-S50.
15. Lipton A, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal randomized phase III trials. Eur J Can. 2012;48:3082-3092.
16. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
17. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
18. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009; 27:5431-5438.
19. KantoffPW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
20. Dicki GJ, et al. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol. 1999;43:476-479.
21. Parker C, et al. Updated analysis of the phase III, double blind, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). ASCO 2013 Abstract.
22. Pisters LL, Dinney CP, Pettaway CA, et al. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999;161:509-514.
23. Cresswell J, Asterling S, Chaudhary M, et al. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int. 2006;97:969-974.
24. Eggener S, Salomon G, Scardino PT, et al. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010;58:57-641
25. Shelley M, Wilt TJ, Coles B, et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 2007;(3):CD005010
26. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:439-443
27. Uchida T, Ohkusa H, Yamashita H, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol. 2006;13:228-233
28. Uchida T, Baba S, Irie A, et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo. 2005;51:651-658
29. Wallace T, Avital I, Stojadinovic A, et al. Multi-parametric MRI-directed focal salvage permanent interstitial brachytherapy for locally recurrent adenocarcinoma of the prostate: a novel approach. J Cancer 2013;4(2):146-151.
30. Ahmed HU, Cathcart P, McCartan N, et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 2012;118(17):4148-55.
31. Gowardhan B, Greene D. Salvage cryotherapy: is there a role for focal therapy? J Endourol 2010;24(5):861-4.
32. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4):1246-54.
33. Dickinson L, Ahmed HU, Kirkham A, et al. A multicenter prospective development study evaluating focal therapy using high intensity focused ultrasound for localized prostate cancer: the INDEX study. Contemp Clin Trials 2013;:s1551.
34. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
35. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005 Mar;173(3):797-802.
36. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s.
37. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, SegaloffA, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-298.
38. WHO. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization Offset publication. 1979.
39. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000;92:205-216.
40. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 2009;45:228-247.
41. Hamaoka T, Madewell JE, PodoloffDA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953.
42. Hamaoka T, Costelloe CM, Madewell JE, et al. Tumour response interpretation with new tumour response criteria vs the World Healt Orgnisation criteria in patients with bone-only metastatic breast cancer. Br J Canc 2010;102:651-657.
43. Hayashi N, Costelloe CM, Hamaoka T, Wei C, et al. A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer 2013;13(1):24-30.
44. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 (suppl 1):122s-150s.
45. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11(14):5223-5232.
46. Bolger JJ, Dearnaley DP, Kirk D, et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bony metastases secondary to prostatic cancer: preliminary report of a multicenter trial. Semin Oncol 1993;20:32-33.
47. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
48. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28(1):126-31.
49. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28(17):2810-16.
50. Lawrentschuk N, Haider MA, Daljeet N, et al. "Prostatic evasive anterior tumors": the role of magnetic resonance imaging. BJU Int 2010;105(9):1231-6.
51. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55(1):1-8.
52. Kazer MW, Psutka SP, Latini DM, Bailey DE. Psychosocial aspects of active surveillance. Curr Opin Urol 2013; 23(3):273-277.
53. Wong LM, Johnston R, Sharma N, Shah NC, Warren AY, Neal DE. General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. BJU Int. 2012 Jul;110(1):24-7.
54. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41.
55. Swindler P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005; 174: 903
56. Kupelian PA, Katcher J, Levin HS et al. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 377: 1043.
57. Lee HM, Solan MJ, Lupinacci P et al. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): Effect of adjuvant radiotherapy. Urology 2004; 64: 84.
58. Ohori M, Wheeler TM, Kattan MW et al. Prog- nostic significance of surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818.
59. Lowe BA and Lieberman SF. Disease recurrence and progression in unrelated pathologic stage T3 prostate cancer: selecting the patient for adju- vant therapy. J Urol 1997; 158: 1452.
60. Bolla M, van Poppel H, Tombal B et al. Postop- erative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018.
61. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 2009; 181: 956.
62. Wiegel T, Bottke D., Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 2009;27: 292
63. Thompson IM, Valicenti RK, Albersen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 2013;190: 443
64. Yee DS, Shariat SF, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2010;108:502-7.
65. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathologic feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004; 171:1122-7.
66. May M, Kaufmann O, Hammermann F, Loy V, Siegsmund M. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2006; 99:539-44.
67. Epstein JI, Srigley J, Grignon D, Humphrey P. Recommendations for the reporting of prostate carcinoma. Human Pathology. 2007;38:1305-9.
68. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91:66-73.
69. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy vs. observations in men with node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: a randomized phase III Eastern Cooperative Oncology Group/Intergroup Trial. N Engl J Med 1999;341:1781-88.
70. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9.
71. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendaions for standard in the reporting of surgical outcomes. J Urol 2007; 177:540.
72. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649.
73. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632-42.
74. King CR. Adjuvant versus salvage radiotherapy for high-riskprostate cancer patients. Semin Radiat Oncol. 2013 23(3):215-21
75. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012;84(1):104-11
76. Stephenson A.J, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol, 2007; 25: 2035-2041
77. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-69.
78. Karlin JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, Wan W, Hagan MP, Anscher MS, Moghanaki D. Identifying appropriate patients for early salvage radiotherapy after prostatectomy. J Urol 2013; 190: 1-6.
79. McGuire BB, Helfand BT, Loeb S, et al. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int 2012; 109(12):1764-9.
80. Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, Jarow JP. Benign prostate glands at the bladder neck margin in robotic vs. open radical prostatectomy. BJU International 2010;105:1446-9.
81. Godoy G, Tareen BU, Lepor H. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Oncology 2009;74:167-170.
82. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labeling for prostate specific antigen in non-prostatic tissues. Pathol Res Pract. 1996; 192:233-7.
83. Holmes GF, Eisele DW, Rosenthal D, Westra WH. PSA immunoreactivity in a Parotid Oncocytoma: A diagnostic pitfall in discriminating primary parotid neoplasms from metastatic prostate cancer. Diagnostic Cytopathology 1998; 19: 221.
84. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancrease and salivary glands: a potential impact on prstate cancer overestimation. J Urology 1996;156:464-8.
85. Mohammadizadeh F, Ranaee M, Zavareh MH, Faghihi M, Saremi M, Eftekhari M. The expression of prostate-specific antigen in invasive breast carcinoma and its relationship with routin clinicopathologic parameter. Adv Biomed Res 2012;1:55.
86. Consensus statement guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035.
87. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965.
88. Ray ME, Thames HD, Levy LB Horwitz EM, Kuban DA, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiation Oncology Biol Phys 2006;64: 1141.
89. Crook JM, Bahadur YA, Bociek RG et al. Radiotherapy for localized prostate carcinomaThe correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer, 1997; 79: 328-336.
90. DeWitt K.D, Sandler H.M, Weinberg V, et al. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology, 2003; 62: 492-496.
91. Hanlon A.L., Diratzouian H., Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys, 2002;53: 297-303.
92. Aref I., Eapen L., Agboola O, et al. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol, 1998;48: 203-207.
93. Cavanaugh S.X., Kupelian P.A, Fuller C.D, et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: Prognostic value of a time-and-PSA threshold model. Cancer, 2004;101: 96-105.
94. Kestin LL, Vicini FA, Ziaja EL et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer, 1999; 86: 1557-1566.
95. Critz FA. Time to achieve a prostate specific antigen nadir of 0.2 ng/ml after simultaneous irradiation for prostate cancer. J Urol, 2002;168: 2434-2438.
96. Ko EC, Stone NN, Stock RG. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys. 2012;83(2):600-7.
97. Zelefsky MJ, Kuban DA, Levy LB, Horwitz EM et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Onc Biol Phys 2007;67(2):327-33.
98. Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urol 2002;60(suppl 2a): 34-9.
99. Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single center experience with third generation cryosurgery for management of organ confined prostate cancer: critical evaluation of short term outcomes, complications, and patient quality of life. J Endourol 2007;21:1521-31.
100. Bahn DK, Lee F, Baldalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: seven year outcomes in the primary treatment of prostate cancer. Urol 2002; 60(suppl 2a):3-11.
101. Pitman M, Shapiro EY, Hruby GW, Truesdale MD, Cheetham PJ, Saad S, Katz AE. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate. The Prostate 2012;72:1802-8.
102. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calles? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2006;64:1355-59.
103. Mazeron R, Bajard A, Montbarbon X, Gassa F, Malet C, Rocher F, Clippe S, Bringeon G, Desmettre O, Pommier P. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence. Radiat Oncol 2012 Mar 26;7:46
104. Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Inj J Radiat Oncol Biol Phys. 2006 62 (2):512-7.
105. Grob BM, Schellhammer PF, Brassil DN, Wright GL Jr. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urol 1994;44:525-9.
106. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27(15):2450-6.
107. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials testosterone: recommendations of the postate cancer clinical trials working group. J Clin Oncol. 2008 Mar 1; 26(7):1148-59.
108. Qin J, Liu X, Laffin B, et al. The PSA (-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propogating cells that resist castration. Cell Stem Cell 2012; 10(5):556-69.
109. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic Patterns of Prostate Cancer: an Autopsy Study of 1589 Patients. Hum Pathol. 2000;31:578-583.
110. Messiou C, Cook G, de Souza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 2009;101:1225-1232.
111. Pollen JJ, Witztum KS, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 1984;142:773-776.
112. Weber G. Enzymology of cancer cells. N Engl J Med 1977;296:541-551.
113. Bouchelouche K, Oher P. Positron emission tomography/computed tomography of urological malignancies: an update review. J Urol 2008; 179:34-45.
114. Pinto F, Totaro A, Palermo G, et al. Imaging in prostate cancer staging: present role and future perspectives. Urol Int 2012;88:125-36.
115. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
116. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23): 5975-9.
117. Neves AF, Araújo TG, Biase WK, et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin. Biochem. 2008;41(14-15): 1191-8.
118. Neves AF, Araújo TG, Biase WK, et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin. Biochem. 2008;41(14-15): 1191-8
119. Ploussard G, Durand X, Xylinas E, Moutereau S, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59(3):422-9.
120. Hayes JD, Pulford DJ. The glutathione S-transferase sugergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
121. Bastian PJ, Ellinger J, Schmidt D, et al. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, gleason grade, PSA value or age? Eur J Med Res 2004;9:2673-7.
122. Murphy GP, Kenny GM, Ragde H. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998;51(suppl 5a):89-97.
123. Israeli RS, Powell CT, Corr JG et al. Expression of the prostate specific membrane antigen. Cancer Res 1994;54(7):1807-11.
124. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992 Mar;147(3 Pt 2):841-5.
125. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:799-800.
126. Couzin J. Metabolite in urine may point to high-risk prostate cancer. Science 2009;323:865.
127. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA. 2004, 291:2713-9.
128. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94:981-90.
129. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006, 25:2846-66.
130. Kirkham AP, Emberton M, Allen C: How good is MRI at detecting and characterising cancer within the prostate? Eur Urol. 2006, 50:1163-74.
131. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000, 164:400-4.
132. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213: 473-80.
133. Haider MA, Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189:323-328.
134. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology. 2009;250:145-151.
135. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate. 2005;62:140-147.
136. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol. 2007;63:335-350.
137. Chen M, Dang HD, Wang C, et al. Prostate Cancer Detection: Comparison of T2-Weighted Imaging, Diffusion-Weighted Imaging, Proton Magnetic Resonance Spectroscopy Imaging, and the Three Techniques Combined. Acta Radiologica. 2008;5:602-610.
138. Vargas HA, Akin O, Franiel T et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology. 2011;259:775.
139. deSouza NM, Riches SF, Vanas NJ et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63:774.
140. Margel D, Yap SA, Lawrentschuk N et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol. 2012;187:1247.
141. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int. 2012;110(1):50-5.
142. Wilson DH, Hanlon DW, Provuncher GK, Change L, et al. Fifth-generation digital immunoassay for prostate specific antigen using single molecule arrays. Clin Chem. 2011;57(12): 1712-1721.
143. Locke JA, Zafarana G, Ishkanian AS, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 2012;18:308-16.
144. Nuzzo PV, Rubagotti A, Zinoli L, Ricci F, Salvi S, Boccardo S, Boccardo F. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. BMC Cancer 2012, 12:625.
145. Freedland SJ, Presti JC Jr, Amling CL. Time trends in biochemical recurrence after radical prostatectomy. Urology 2003; 61:736-741
146. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-523
147. Panebianco V, Barchetti F, Sciarra A, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013; 23:1745-1752
148. Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-769
149. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8:475-487
150. Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. Am J Roentgenol. 2011;197: 408-14.
151. Westphalen AC, Reed GD, Vinh PP, et al. Multiparametric 3T endorectal MRI after externalbeam radiation therapy for prostate cancer. J Magn Reson Imaging. 2012;36:430-7.
152. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233:441-448
153. Nunez R, Macapinloc HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46-55.
154. Brogsitter C, Zophel K, Kotzerke J. (18)F-choline, (11)C-choline and (11)C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 2013; 40(suppl 1):18-27.
155. Watahiki A, Macfarlane RJ, Gleave ME, et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. In J Mol Sci 2013;14(4):7757-70.
156. Yoon HY, Kim YW, Kang HW, et al. Pyrosequencing analysis of APC methylation level in human prostate tissues: a molecular marker for prostate cancer. Korean J Urol. 2013 Mar;54(3):194-8.
157. Som A, Tu SM, Liu J, et al. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 2012;107(9):1547-53